These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 952715)

  • 1. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.
    Alberts DS; Van Daalen Wetters T
    Br J Cancer; 1976 Jul; 34(1):64-8. PubMed ID: 952715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.
    Herman EH; Young RS
    Cancer Treat Rep; 1979; 63(11-12):1771-9. PubMed ID: 526912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.
    Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER
    Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical studies with rubidazone.
    Benjamin RS; Keating MJ; Swenerton KD; Legha S; McCredie KB
    Cancer Treat Rep; 1979 May; 63(5):925-9. PubMed ID: 287557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
    Tong GL; Cory M; Lee WW; Henry DW
    J Med Chem; 1978 Aug; 21(8):732-7. PubMed ID: 690999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rubidazone in the treatment of recurrent acute leukemia in children. A Pediatric Oncology Group Study.
    Ragab AH; Boyett JM; Frankel L; Falletta J
    Cancer; 1986 Apr; 57(8):1461-3. PubMed ID: 3948126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitumour activity of new daunorubicin and adriamycin analogues.
    Arcamone F; Bernardi L; Patelli B; Giardino P; Di Marco A; Casazza AM; Soranzo C; Pratesi G
    Experientia; 1978 Oct; 34(10):1255-7. PubMed ID: 570116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
    Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
    Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of allopurinol on cyclophosphamide antitumor activity.
    Alberts DS; van Daalen Wetters T
    Cancer Res; 1976 Aug; 36(8):2790-4. PubMed ID: 1277189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E; Menconi E; Barzi AM
    Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 and 2 trial of rubidazone in patients with acute leukemia.
    Benjamin RS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
    Cancer Res; 1977 Dec; 37(12):4623-8. PubMed ID: 270389
    [No Abstract]   [Full Text] [Related]  

  • 19. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinetic response to cultured human lymphoid cells to rubidazone.
    Barlogie B; Drewinko B; Benjamin RS
    J Natl Cancer Inst; 1978 Feb; 60(2):279-82. PubMed ID: 621746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.